Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
In 1965, when Stein was 18, his father, a retired managing director of The Distillers Company, who suffered from bipolar disorder, killed himself by jumping from a cliff near the family's holiday home at Trevose Head. Stein met his first wife Jill Newstead in Padstow. They married in 1975, both aged 28, and set up their restaurant and hotel business. Stein has three sons with Jill: Edward, Jack, and Charles, who are involved in the family business. Stein met Sarah Burns, 20 years his junior, in Australia in 1997, when he was 50. She was also married, and working as a publicity manager for Australia Gourmet Traveller magazine. Stein and Burns had a secret five-year affair before Jill found out in 2002. She and Stein separated in 2002 and divorced in 2007, but agreed to continue to run the business together. Burns divorced in 2003, and she and Stein married on 7 October 2011. Stein has a brother, John, and a sister, Henrietta. He also has a half-brother, Jeremy, his mother's son from her first marriage. He is the uncle of DJ and music producer Judge Jules, and the artist Lucy Stein. In 2022, Stein underwent open heart surgery at the Royal Brompton Hospital to repair a defective heart valve. Appearing live on BBC's The One Show in October 2023, promoting his book, Simple Suppers, he shared that his heart surgery experience had inspired his back to basics recipes but he inadvertently used a swear word and the show's host and Stein had to apologise for the error.
=== Industrial applications === Formaldehyde is a common precursor to more complex compounds and materials. In approximate order of decreasing consumption, products generated from formaldehyde include urea formaldehyde resin, melamine resin, phenol formaldehyde resin, polyoxymethylene plastics, 1,4-butanediol, and methylene diphenyl diisocyanate. The textile industry uses formaldehyde-based resins as finishers to make fabrics crease-resistant.
According to The Washington Post, the coalition forces regularly use "torture-like" methods during the interrogation of suspects. Such methods were reportedly applied to people to find the hiding place of Saddam Hussein in Operation Red Dawn. British troops have also on occasion been accused of abusing Iraqi detainees. Such treatment violates article 17 of the Third Geneva Convention and the USA and Britain's official policies on combat and occupation. Despite numerous complaints by Amnesty International and Human Rights Watch, it took a year before the first US soldier was court-martialed for their actions concerning abuse of Iraqis.
=== Hartig net === The Hartig net is formed by an ingrowth of hyphae (often originating from the inner part of the surrounding mantle) into the root of the plant host. The hyphae penetrate and grow in a transverse direction to the axis of the root, and thus form a network between the outer cells of the root axis. In this region fungal and root cells touch, and this is where nutrient and carbon exchange occurs. The depth of penetration differs between species. In Eucalyptus and Alnus the Hartig net is confined to the epidermis, whereas in most gymnosperms the hyphae penetrate more deeply, into the cortical cells or the endodermis. In many epidermal types elongation of cells along the epidermis occurs, increasing surface contact between fungus and root cells. Most cortical type Hartig nets do not show this elongation, suggesting different strategies for increasing surface contact among species.
The Islamic Health Authority's website says it has "provided services for the activity of the Hezbollah fighters against the Zionist occupation." According to UNIFIL, Hezbollah has used the environmental NGO "Green Without Borders" to provide direct cover for Hezbollah's military operations by "unlawful construction of military outposts along the Blue Line." Hezbollah has also launched rockets from UNIFL positions. The IDF reported that 25 rockets were launched from UNIFL positions in October 2024 and said that it discovered hundreds of weapons, including firearms, grenades, and rocket launchers, stored in compounds located near UNIFIL posts in southern Lebanon. After the 20 September 2024 Beirut attack which killed major Radwan Force commanders in the densely populated Dahieh suburbs, Daniel Hagari said that the commanders were holding a meeting "gathered underground under a residential building in the heart of the Dahieh neighbourhood, hiding among Lebanese civilians, using them as human shields." On 23 September 2024, the IDF began posting pictures and videos of what it claimed was evidence of Hezbollah placing weapons in people's homes. They also released video footage of secondary explosions after targeting buildings which it says are from Hezbollah munitions stored in residential areas.
Sources: en.wikipedia.org
High-level waste (HLW) is produced by nuclear reactors and the reprocessing of nuclear fuel. The exact definition of HLW differs internationally. After a nuclear fuel rod serves one fuel cycle and is removed from the core, it is considered HLW. Spent fuel rods contain mostly uranium with fission products and transuranic elements generated in the reactor core. Spent fuel is highly radioactive and often hot. HLW accounts for over 95% of the total radioactivity produced in the process of nuclear electricity generation but it contributes to less than 1% of volume of all radioactive waste produced in the UK. Overall, the 60-year-long nuclear program in the UK up until 2019 produced 2150 m3 of HLW. The radioactive waste from spent fuel rods consists primarily of cesium-137 and strontium-90, but it may also include plutonium, which can be considered transuranic waste. The half-lives of these radioactive elements can differ quite extremely. Some elements, such as cesium-137 and strontium-90 have half-lives of approximately 30 years. Meanwhile, plutonium has a half-life that can stretch to as long as 24,000 years. The amount of HLW worldwide is increasing by about 12,000 tonnes per year. A 1000-megawatt nuclear power plant produces about 27 tonnes of spent nuclear fuel (unreprocessed) every year. For comparison, the amount of ash produced by coal power plants in the United States is estimated at 130,000,000 t per year and fly ash is estimated to release 100 times more radiation than an equivalent nuclear power plant.
== Gastrointestinal == The gastrointestinal tract has multiple trophic factors that regulate growth. The gut contains peptides that stimulate mucosal growth of stomach, colon, and small bowl cells. The hormones secreted control other gastrointestinal functions like regulation of secretion, motility, digestion and absorption.
=== Sport === Donough O'Brien (1879–1953), was a Welsh-born Irish cricketer. Ray Williams (born 1959), is a weightlifting Commonwealth Games gold medallist. Tony Roberts (born 1969), is Welsh international footballer with 614 club caps Gareth Evans (born 1986), weightlifter, Commonwealth gold medalist and 2012 Summer Olympics, lives in the town. Alex Lynch (born in 1995), a footballer with over 100 club caps, educated in Ysgol Uwchradd Caergybi.
=== Familial dysautonomia === Familial dysautonomia is a genetic condition that can be associated with a lack of overflow tears (alacrima) during emotional crying. Obstruction of the punctum, nasolacrimal canal, or nasolacrimal duct can cause even normal levels of the basal tear to overflow onto the face (epiphora), giving the appearance of constant psychic tearing. This can have significant social consequences.
Sources: en.wikipedia.org
In March 2009, the company unveiled the alternate slogan "You 'Kin Do It!" and launched a $100 million ad campaign promotion. In 2017, the company announced that it would begin testing the name of simply "Dunkin'" at some retail locations, as they would like to be thought of as a destination for coffee, its most profitable product. The branding would be implemented in other locations in the latter half of 2018 if it was successful. The brand announced that it would be known simply as Dunkin' in September 2018. In April 2018, Dunkin' Donuts teamed up with the Massachusetts shoe manufacturer, Saucony, to produce a strawberry-frosted doughnut themed running shoe to commemorate the 122nd running of the Boston Marathon. The Saucony X Dunkin' Kinvara 9 came in a doughnut box and the heel of the shoe was covered in rainbow sprinkles. The chain is a favorite among celebrities. Ben Affleck began starring in commercials for the company along with his then-wife Jennifer Lopez in February 2023. The first aired during Super Bowl LVII. They starred in a follow up that first aired during Super Bowl LVIII, along with Affleck's long-time friend, Matt Damon, and former NFL star Tom Brady. The chain then announced it would add Affleck's specific order, an iced coffee with cream, sweet cold foam, and cinnamon sugar, via its limited-time DunKings Menu. On July 29, 2025, Dunkin' launched a campaign dubbed the "King of Summer", featuring actor Gavin Casalegno advertising its fruit-flavored Summer Refreshers.
== Partnerships and Agreements == Licensing agreements for Biomatrica technologies were signed with Qiagen in 2007 and 2009. Following the launch of DNAstable, the company gained the interest of law enforcement organizations, such as the California Department of Justice, which sought to stabilize DNA samples from crime scenes for forensics purposes. Other law enforcement organizations, including sheriffs’ departments in Orange County, CA Los Angeles, CA, and Palm Beach, FL, have adopted ambient temperature forensic sample management systems based on Biomatrica's technologies. Also in 2010, Biomatrica signed a collaborative research and development agreement (CRADA) with United States Army Medical Research Institute for Infectious Diseases (USAMRIID) to develop and test new technologies for ambient temperature stabilization of clinical and biological samples. The same year, Biomatrica began a partnership agreement with the U.S. National Cancer Institute (NCI) for biomarker stabilization and SAIC-Frederick to improve molecular analysis of tumors. In 2011, the company announced a partnership agreement with In-Q-Tel, an investment firm that identifies technologies to support the mission of the U.S. intelligence community. In 2014, Biomatrica and American Type Tissue Culture (ATCC) signed a licensing agreement for Biomatrica to supply its DNA & RNA stabilization reagents to the ATCC for use in the latter company's DNA and RNA standards. In the same year, Biomatrica and Sigma-Aldrich signed an agreement for the worldwide distribution of Biomatrica's stabilization reagents.
As the number of confirmed COVID-19 cases in the state continued to rise, on March 15, Newsom urged people 65 and older and those with chronic health conditions to isolate themselves from others. He also called on bars and brewery and winery tasting rooms to close their doors to patrons. Some local jurisdictions had mandatory closures. The closures were extended to movie theaters and health clubs. He asked restaurants to stop serving meals inside their establishments and offer take-out meals only. His statewide stay-at-home order became mandatory on March 19. It limited in-house gatherings, including religious gatherings and Bible studies. It allowed movement outside the home for necessities or recreation, but people were required to maintain a safe distance apart. Activity "needed to maintain continuity of operation of the federal critical infrastructure sectors, critical government services, schools, childcare, and construction" was excluded from the order. Essential services such as grocery stores and pharmacies remained open. Newsom provided state funds to pay for protective measures such as hotel room lodging for hospital and other essential workers fearing returning home and infecting family members. By April 26, he had issued 30 executive orders under the state of emergency while the legislature had not been in session. On April 28, Newsom and the governors of Oregon and Washington announced a "shared approach" for reopening their economies.
Beta hairpin Extremely common. Two antiparallel beta strands connected by a tight turn of a few amino acids between them. Greek key Four beta strands, three connected by hairpins, the fourth folded over the top. Omega loop A loop in which the residues that make up the beginning and end of the loop are very close together. Helix-loop-helix Consists of alpha helices bound by a looping stretch of amino acids. This motif is seen in transcription factors. Zinc finger Two beta strands with an alpha helix end folded over to bind a zinc ion. Important in DNA binding proteins. Helix-turn-helix Two α helices joined by a short strand of amino acids and found in many proteins that regulate gene expression. Nest Extremely common. Three consecutive amino acid residues form an anion-binding concavity. Niche Extremely common. Three or four consecutive amino acid residues form a cation-binding feature.
For example, in biochemistry it is widely used to separate charged molecules such as proteins. An important area of the application is extraction and purification of biologically produced substances such as proteins (amino acids) and DNA/RNA. Ion-exchange processes are used to separate and purify metals, including separating uranium from plutonium and the other actinides, including thorium, neptunium, and americium. This process is also used to separate the lanthanides, such as lanthanum, cerium, neodymium, praseodymium, europium, and ytterbium, from each other. The separation of neodymium and praseodymium was a particularly difficult one, and those were formerly thought to be just one element didymium – but that is an alloy of the two. There are two series of rare-earth metals, the lanthanides and the actinides, both of whose families all have very similar chemical and physical properties. Using methods developed by Frank Spedding in the 1940s, ion-exchange processes were formerly the only practical way to separate them in large quantities, until the development of the "solvent extraction" techniques that can be scaled up enormously. A very important case of ion-exchange is the plutonium-uranium extraction process (PUREX), which is used to separate the plutonium (mainly [[plutonium-239|239Pu) and the uranium (in that case known as reprocessed uranium) contained in spent fuel from americium, curium, neptunium (the minor actinides), and the fission products that come from nuclear reactors. Thus the waste products can be separated out for disposal.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.